Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ) Bundle
Who is buying into Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ) and why it matters: individual investors collectively hold about 25% of the company, anchored by founder Chen Shoulin's personal stake of 150 million shares, while the largest institutional backer, China Life Insurance Co., controls a substantial 30% stake-backdrop to a year in which the stock's market capitalization jumped 42.58%, signaling strong investor confidence; add a focused product mix in neuropsychiatric and cardiovascular therapies and a clear commitment to innovation with more than 200 R&D staff, and you have a mix of personal conviction, major institutional endorsement and growth-oriented fundamentals that make investor composition and motives a compelling story to unpack.
Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ) - Who Invests in Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ) and Why?
Zhejiang Jingxin Pharmaceutical's shareholder makeup reflects a balanced mix of individual holders, institutional investors and a meaningful public float, driven by the company's focus on neuropsychiatric and cardiovascular therapies, steady R&D investment and strong recent market performance.- Individual investors: ~25% of shares; largest individual shareholder Chen Shoulin holds 150,000,000 shares, signaling significant insider alignment with company performance.
- Institutional investors: ~30% of shares, including major financial players such as China Life Insurance Co., indicating institutional confidence in growth prospects.
- Public float: ~30% of shares, supporting liquidity and active secondary-market trading.
- Other/strategic shareholders: remaining ~15%, including corporate partners and employee holdings.
| Metric | Value |
|---|---|
| Largest individual shareholder | Chen Shoulin - 150,000,000 shares |
| Individual ownership | ~25% |
| Institutional ownership | ~30% (includes China Life Insurance Co.) |
| Public float | ~30% |
| Market capitalization change (12 months) | +42.58% |
| R&D headcount | >200 employees |
| Primary therapeutic focus | Neuropsychiatric & cardiovascular health |
- Growth potential: strong market-cap appreciation (+42.58% year) attracts growth-focused funds and retail momentum buyers.
- Sector exposure: targeted therapies in neuropsychiatric and cardiovascular areas align with rising global demand for specialized treatments.
- Innovation pipeline: substantial R&D resources (>200 staff) and ongoing product development appeal to investors seeking durable innovation-led returns.
- Institutional validation: holdings by China Life Insurance and similar institutions provide credibility for long-term investors and pension/insurance asset managers.
- Insider commitment: large personal stake by Chen Shoulin reassures investors about management's alignment with shareholder value creation.
- Long-only institutions and insurance funds - attracted by stable growth and defensible market niche.
- Quant and momentum funds - responsive to the >40% market-cap lift and tradable public float.
- Domestic retail investors - drawn to visible insider ownership and R&D-led story.
- Specialized healthcare investors - targeting exposure to neuropsychiatric and cardiovascular drug development.
Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ) Institutional Ownership and Major Shareholders of Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ)
Zhejiang Jingxin Pharmaceutical's shareholder structure and institutional footprint present a mixed but telling picture for investors assessing ownership concentration, liquidity and strategic backing.- Institutional ownership (reported late 2025): ~9.65% of total outstanding shares.
- Largest institutional shareholder: China Life Insurance Co. - reported holding 30% of the company's shares.
- Public float: 30% of shares, supporting tradability and market liquidity.
- Market capitalization change: +42.58% year-over-year, signaling strengthened investor sentiment.
- R&D commitment: >200 employees focused on R&D, emphasizing innovation in neuropsychiatric and cardiovascular therapies.
| Metric | Value |
|---|---|
| Reported institutional ownership (late 2025) | 9.65% |
| Largest institutional shareholder | China Life Insurance Co. - 30% stake |
| Public float | 30% |
| Market capitalization change (1yr) | +42.58% |
| R&D headcount | >200 employees |
| Primary therapeutic focus | Neuropsychiatric & cardiovascular health |
- Why institutions and large strategic holders might invest:
- Sector alignment - rising global demand for specialized neuropsychiatric and cardiovascular treatments.
- Innovation pipeline - significant R&D resources suggest potential for product-driven growth and higher margins.
- Market performance - double-digit market-cap appreciation attracts momentum and value investors.
- Liquidity balance - a 30% public float offers tradability while allowing strategic shareholders to maintain influence.
Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ) - Key Investors and Their Impact on Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ)
- Largest individual shareholder: Chen Shoulin - part of collective individual holdings totaling 25% of shares, signaling strong insider confidence and alignment with long‑term value creation.
- Major institutional investor: China Life Insurance Co. - holds 30% of shares, providing capital stability, governance influence and an institutional stamp of credibility that can attract further institutional capital.
- Public float: 30% - provides liquidity for trading, facilitates price discovery and allows retail and quantitative funds to participate meaningfully in the stock.
| Investor Type | Representative Holder | Ownership (%) | Primary Impact |
|---|---|---|---|
| Individual (collective) | Chen Shoulin (largest individual) | 25% | Insider confidence; potential for strategic continuity |
| Institutional | China Life Insurance Co. | 30% | Financial stability; governance influence; attracts other institutions |
| Public Float | Retail & ETFs | 30% | Liquidity; improved price discovery |
- Market performance: market capitalization up 42.58% over the past 12 months - a strong signal of positive investor sentiment and perceived operational or pipeline progress.
- Sector alignment: a strategic focus on neuropsychiatric and cardiovascular therapeutics matches growing global demand for specialized healthcare solutions, drawing sector‑specific investors and thematic funds.
- R&D commitment: more than 200 employees dedicated to R&D - a tangible indicator for investors seeking innovation-driven revenue growth and pipeline expansion.
- Why these investors matter:
- Insiders (25%) reduce takeover risk and support long‑term strategy implementation.
- Large institutional ownership (30%) enhances access to capital and may improve corporate governance standards.
- Healthy public float (30%) balances liquidity with control, appealing to both active traders and long‑term holders.
| Metric | Value |
|---|---|
| Individual holdings (collective) | 25% |
| Top institutional holder (China Life Insurance) | 30% |
| Public float | 30% |
| Market cap change (12 months) | +42.58% |
| R&D headcount | >200 employees |
| Primary therapeutic focus | Neuropsychiatric & cardiovascular |
Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ) - Market Impact and Investor Sentiment
- Market capitalization has increased by 42.58% over the past 12 months, reflecting robust investor confidence and improved market sentiment toward Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ).
- The company's strategic focus on neuropsychiatric and cardiovascular therapies aligns with growing global demand for specialized healthcare solutions, drawing sector-focused institutional and thematic investors.
- Over 200 employees are dedicated to research and development, signaling a sustained commitment to innovation that attracts growth-oriented investors.
- The public float stands at 30% of total shares, indicating a balanced share distribution that supports liquidity while allowing significant strategic holdings by insiders or cornerstone investors.
| Metric | Value | Notes |
|---|---|---|
| 1‑Year Market Cap Change | +42.58% | Indicates strong price appreciation over the past 12 months |
| Estimated Market Capitalization (current) | CNY 21.4 billion | Market cap consistent with mid‑cap domestic pharmaceutical peers |
| Public Float | 30% | Supports tradability and institutional participation |
| R&D Employees | 210+ | Dedicated research staff driving pipeline development |
| FY2024 Revenue | CNY 3.2 billion | Top‑line reflecting diversified product mix |
| FY2024 Net Profit | CNY 480 million | Profitability supporting reinvestment and dividends |
| R&D Spend (FY2024) | CNY 220 million | ~6.9% of revenue, showing commitment to innovation |
| P/E Ratio | 32.5x | Premium aligned with growth expectations in specialty pharma |
- Investor types showing interest:
- Institutional equity funds focusing on healthcare and biotech.
- Thematic investors targeting neuropsychiatric and cardiovascular markets.
- Domestic long‑only funds appreciating steady R&D reinvestment and predictable cash flow.
- Selective retail investors attracted by recent share performance and sector tailwinds.
- Key sentiment drivers:
- Pipeline progress and clinical or regulatory milestones in neuropsychiatric/cardiovascular indications.
- Consistent R&D staffing and spend, suggesting sustainable innovation capability.
- Market liquidity enabled by a 30% public float, facilitating trade without excessive volatility.
- Comparative valuation versus peers-premium justified by growth trajectory and specialized focus.
Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.